---
title: "Dupixent (dupilumab) in atopic dermatitis: Indication questions"
description: "Indication questions on Dupixent (dupilumab) in atopic dermatitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names. Questions: Who is Dupixent approved for in atopic dermatitis (eczema)? When was Dupixent approved for atopic dermatitis? What is the generic name for Dupixent? 3 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Dupixent (dupilumab) in atopic dermatitis: Indication questions

Manufacturer: sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.  
Prescribing information: [Dupixent](https://www.regeneron.com/downloads/dupixent_fpi.pdf)

## Indication

<a id="dupixent-ad-indication"></a>

### Who is Dupixent approved for in atopic dermatitis (eczema)?

> “DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose
> disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without
> topical corticosteroids.”

Source: [DUPIXENT: DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis That is Uncontrolled, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/#:~:text=DUPIXENT%20is%20indicated%20for%20the,topical%20corticosteroids.)

<a id="dupixent-ad-approval-history"></a>

### When was Dupixent approved for atopic dermatitis?

> “It has been 9 years since initial FDA approval of DUPIXENT in AD in adults.<sup>1,a</sup>”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=It%20has%20been%209%20years,of%20DUPIXENT%20in%20AD%20in)

On the page, select: How long has DUPIXENT been on the market?

> “FDA approved since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years), and 2022 for infants to preschoolers (aged 6 months to 5 years) with uncontrolled moderate-to-severe AD.”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=FDA%20approved%20since%202017%20for,years%29%20with%20uncontrolled%20moderate%2Dto%2Dsevere%20AD.)

On the page, select: How long has DUPIXENT been on the market?

## Drug names

<a id="dupixent-generic-name"></a>

### What is the generic name for Dupixent?

> “DUPIXENT<sup>®</sup> (dupilumab) injection, for subcutaneous use”

Source: [DUPIXENT: dupixent_fpi.pdf, page 1, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=1)

> “Dupilumab, an interleukin-4 receptor alpha antagonist, is a human monoclonal antibody of the 
> IgG4 subclass that binds to the IL-4Rα subunit and inhibits IL-4 and IL-13 signaling. Dupilumab 
> has an approximate molecular weight of 147 kDa.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 31, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=31)

## Related pages
- [Medical information: Dupixent (dupilumab): Atopic dermatitis](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis)
- [Pharmacology](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/guidelines)
